CU6.AX
Clarity Pharmaceuticals Ltd
ASXAUDEQUITY
DELAYED
Last price
2.48
▼ 0.14 (5.34%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
2.58
Prev close
2.62
Day high
2.60
Day low
2.44
Volume
2.38M
Market cap
—
P/E (TTM)
—
52W range
1.80 – 5.87
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-5.70%
-4.3%
1M
-3.12%
-6.9%
3M
-8.49%
-11.6%
6M
-35.08%
-46.1%
YTD
-26.63%
-38.9%
1Y
-32.05%
-52.1%
3Y
+125.45%
+51.3%
5Y
+68.14%
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Research & development | $66.88M | $45.78M | $31.46M | $18.90M | +46.1% |
| Selling, general & admin | $6.18M | $5.48M | $2.03M | $9.07M | +12.8% |
| Total operating expense | $78.56M | $56.31M | $36.16M | $30.29M | +39.5% |
| Operating income | -$78.56M | -$56.31M | -$36.16M | -$30.29M | -39.5% |
| Net interest income | $4.76M | $2.77M | $1.86M | $95.09K | +71.8% |
| Pre-tax income | -$63.88M | -$42.03M | -$24.50M | -$23.74M | -52.0% |
| Tax provision | $416.51K | $295.15K | $103.20K | $17.63K | +41.1% |
| Net income | -$64.30M | -$42.32M | -$24.60M | -$23.75M | -51.9% |
| Net income to common | -$64.30M | -$42.32M | -$24.60M | -$23.75M | -51.9% |
| Basic EPS | -0.20 | -0.16 | -0.09 | -0.10 | -29.7% |
| Diluted EPS | -0.20 | -0.16 | -0.09 | -0.10 | -29.7% |
| EBIT | -$78.56M | -$56.31M | -$36.16M | -$30.29M | -39.5% |
| EBITDA | -$78.37M | -$56.15M | -$36.06M | -$30.24M | -39.6% |
| Basic shares | 319.20M | 273.16M | 260.41M | 248.47M | +16.9% |
| Diluted shares | 319.20M | 273.16M | 260.41M | 248.47M | +16.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $47.68M | $47.90M | $31.21M | $55.34M | -0.5% |
| Cash & short-term investments | $84.12M | $136.51M | $65.01M | $92.34M | -38.4% |
| Total current assets | $100.61M | $154.06M | $76.68M | $99.55M | -34.7% |
| Property, plant & equipment | $552.46K | $554.80K | $206.14K | $260.09K | -0.4% |
| Total assets | $101.17M | $154.63M | $76.90M | $99.82M | -34.6% |
| Total current liabilities | $10.38M | $8.09M | $7.54M | $7.51M | +28.3% |
| Total liabilities | $10.94M | $8.33M | $7.72M | $7.59M | +31.3% |
| Retained earnings | -$176.99M | -$112.70M | -$70.37M | -$45.80M | -57.1% |
| Shareholder equity | $90.23M | $146.30M | $69.18M | $92.24M | -38.3% |
| Working capital | $90.23M | $145.97M | $69.14M | $92.04M | -38.2% |
| Net tangible assets | $90.23M | $146.30M | $69.18M | $92.24M | -38.3% |
| Shares issued | 321.47M | 311.65M | 132.53M | 258.74M | +3.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$182.74K | -$504.00K | -$46.56K | -$213.15K | +63.7% |
| Investing cash flow | $51.99M | -$55.31M | $3.15M | -$26.71M | +194.0% |
| Share buybacks | -$193.39K | -$6.65M | -$12.75K | -$5.60M | +97.1% |
| Financing cash flow | $2.21M | $115.21M | $231.58K | $86.93M | -98.1% |
| Free cash flow | -$54.95M | -$43.74M | -$27.55M | -$13.53M | -25.6% |
| End cash position | $47.68M | $47.90M | $31.21M | $55.34M | -0.5% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2025-06-30 | YoY |
|---|---|---|
| Cash & equivalents | $47.68M | |
| Cash & short-term investments | $84.12M | |
| Total current assets | $100.61M | |
| Property, plant & equipment | $552.46K | |
| Total assets | $101.17M | |
| Total current liabilities | $10.38M | |
| Total liabilities | $10.94M | |
| Retained earnings | -$176.99M | |
| Shareholder equity | $90.23M | |
| Working capital | $90.23M | |
| Net tangible assets | $90.23M | |
| Shares issued | 321.47M |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.67
-7.08% from price
SMA 20
2.53
-1.88% from price
SMA 50
2.37
+4.73% from price
SMA 100
2.58
-3.93% from price
SMA 200
3.02
-17.91% from price
EMA 12
2.59
-4.06% from price
EMA 26
2.53
-1.82% from price
EMA 50
2.50
-0.72% from price
RSI (14)
48.2
Neutral
MACD (12,26,9)
0.06
Hist -0.02
ATR (14)
0.20
7.93% of price
Realised vol 30D
74.6%
Annualised
Bollinger upper
3.01
20, 2σ
Bollinger lower
2.05
20, 2σ
50 / 200 cross
Death
2.37 vs 3.02
Trend bias
Below 200
-17.91%
Risk profile
Beta vs SPY
0.59
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
74.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-68.2%
Peak to trough
Max drawdown 5Y
-83.4%
Peak to trough
ATR 14
0.20
7.93% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Senators Plan a Clarity Act Vote on Sept. 15. What Happens Next for Crypto?
Motley Fool · 13m ago
Is Honda Motor (TSE:7267) Still Worth Buying As Its Valuation Debate Heats Up?
Simply Wall St. · 13m ago
How Strong Quarterly Results And New Tech Partnerships At Halliburton (HAL) Have Changed Its Investment Story
Simply Wall St. · 13m ago
Bumble (BMBL) Stock Fair Value Falls As Analysts Cut Targets And Question Recovery
Simply Wall St. · 14m ago
Should Strong Q2 Results And New FDA-Authorized ZYN ULTRA Pouches Require Action From Philip Morris (PM) Investors?
Simply Wall St. · 14m ago
Interfor (TSX:IFP) Stock Sees Fair Value Lift After Higher Analyst Targets
Simply Wall St. · 14m ago
OSI Systems (OSIS) Could Be 26% Undervalued As Earnings Raise Fresh Valuation Questions
Simply Wall St. · 14m ago
Nebius Just Raised $5 Billion in Convertible Notes Against a $1.4 Billion Revenue Base. Are We In a Bubble?
Motley Fool · 17m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.